Skip to main content
39 search results for:

EASD 2021 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 21-09-2022 | EASD 2022 | News | Article

    Skin reactions rarely lead to diabetes device discontinuation

    “The discontinuation is quite low,” presenter Jean-Pierre Riveline (Lariboisière Hospital, Paris, France) told attendees of the 58th EASD Annual Meeting in Stockholm, Sweden, “but it’s not zero.”

  2. 21-09-2022 | EASD 2022 | News | Article

    isCGM benefits sustained for at least 2 years

    All people who started on an isCGM in North Denmark during the study period of 2020–2021 received a 2-hour group training session plus half-hour individual session at baseline and 3 months later.

  3. 01-10-2021 | EASD 2021 | News | Article

    ADA/EASD publish consensus report on type 1 diabetes management

    The newly published ADA/EASD consensus report on the management of type 1 diabetes provides a comprehensive overview of the care required to help people with the condition live a full and healthy life.

  4. 05-10-2021 | EASD 2021 | News | Article

    Socioeconomic inequalities impact multiple aspects of diabetes care

    For example, men in the most versus the least deprived quintiles had a 1.58-fold increased type 2 diabetes risk in 2007 and a 1.89-fold increased risk in 2021. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021 (presentation 332) EASD Annual Meeting; Sept 27–Oct 1, 2021 (presentation 308)

  5. 05-10-2021 | EASD 2021 | News | Article

    Nerve fiber dysfunction evident early in type 1 and type 2 diabetes course

    Both small and large nerve fiber impairment can be detected among people with well-controlled recent-onset type 1 or type 2 diabetes, and may regress with time, shows German research presented at the virtual 57th EASD Annual Meeting.

  6. 04-10-2021 | EASD 2021 | News | Article

    Improved renal cortical oxygenation may contribute to dapagliflozin benefits

    Randomized trial findings presented at the virtual 57th EASD Annual Meeting suggest that treatment with a high dose of the SGLT2 inhibitor dapagliflozin may improve renal cortical oxygenation in people with type 1 diabetes and albuminuria.

  7. play
    08-10-2021 | EASD 2021 | Conference coverage | Video

    The ADA/EASD type 1 diabetes consensus: Comprehensive and up to date

    Parth Narendran gives his highlights of the ADA/EASD type 1 diabetes management consensus report, and explains how it can support clinicians to deliver improved services for their patients.

  8. 01-10-2021 | EASD 2021 | News | Article

    Higher risk for incident CV, renal disease with type 1 vs type 2 diabetes

    People with type 1 diabetes have a greater risk for incident cardiovascular and renal disease than those with type 2 diabetes, suggest findings from a French nationwide observational study presented at the virtual 57th EASD Annual Meeting.

  9. 01-10-2021 | EASD 2021 | News | Article

    Use of SGLT2 inhibitors beneficial in older adults with type 2 diabetes

    Among older people with type 2 diabetes, use of SGLT2 inhibitors is associated with improved glycemic control and a favorable safety profile, suggests research reported at the virtual 57th EASD Annual Meeting.

  10. 29-09-2021 | EASD 2021 | News | Article
    News in brief

    Obstructive sleep apnea risk increased in type 1 diabetes

    People with type 1 diabetes have an increased risk for developing obstructive sleep apnea, researchers have reported at the virtual 57th EASD Annual Meeting.

  11. 29-09-2021 | EASD 2021 | News | Article

    Age at type 1 diabetes diagnosis is decreasing within families

    The age at diagnosis of type 1 diabetes has decreased substantially across successive generations, show study findings presented at the virtual 57th EASD Annual Meeting.

  12. 28-09-2021 | EASD 2021 | News | Article

    DKA presentation similar for type 1 and type 2 diabetes

    Diabetic ketoacidosis is three times more common with type 1 diabetes than with type 2 diabetes, but episode presentation and severity are similar between the two groups, show data presented at the virtual 57th EASD Annual Meeting.

  13. 28-09-2021 | EASD 2021 | News | Article

    Poor hypoglycemia awareness ‘highly prevalent’ in children, young people with type 1 diabetes

    Impaired hypoglycemia awareness is present in a substantial proportion of children and young people with type 1 diabetes and is associated with an increased risk for severe hypoglycemia, suggests research presented at the virtual 57th EASD Annual Meeting.

  14. play
    01-10-2021 | EASD 2021 | Conference coverage | Video

    Management of type 1 diabetes: ADA/EASD consensus report

    Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration.

  15. 29-09-2021 | EASD 2021 | News | Article

    TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

    He said that when glycemia is the priority, characteristics such as BMI and eGFR can help guide prescribing, but cautioned that “drug choice will need to consider other priorities than glycemia,” including comorbidities and adverse events. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

  16. 05-10-2021 | EASD 2021 | News | Article
    News in brief

    Semaglutide treatment may reduce systemic inflammation

    She said that further insights should come from the ongoing SOUL and SELECT trials, which are assessing the cardioprotective ability of oral semaglutide and weekly injectable semaglutide 2.4 mg, respectively. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

  17. 05-10-2021 | EASD 2021 | News | Article

    Omnipod DASH benefits confirmed in real-world study

    She concluded: “These patient outcomes really provide evidence that the use of the Omnipod DASH was associated with reductions in A1c but also hypoglycemic events after 90 days of use for all the population of children, adolescents, and adults with type 1 diabetes.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

  18. 04-10-2021 | EASD 2021 | News | Article

    Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

    He added that the results are consistent with those of the randomized, controlled BRIGHT trial and the real-world DELIVER Naïve D study and may “contribute to overcoming clinical inertia in initiation of basal insulin and dose titration in insulin naïve people with type 2 diabetes.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

  19. 04-10-2021 | EASD 2021 | News | Article

    SoliMix trial supports iGlarLixi for type 2 diabetes

    “These results show that the once-daily FRC, iGlarLixi, is an efficacious and well-tolerated regimen, providing better glycemic control with weight benefit and less hypoglycemia compared with premix BIAsp 30 as an alternative for advancing therapy in people with type 2 diabetes previously suboptimally controlled with basal insulin plus oral antihyperglycemic drugs,” McCrimmon concluded. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

  20. 01-10-2021 | EASD 2021 | News | Article

    HARPdoc reduces severe hypoglycemia, boosts mental health in impaired hypoglycemia awareness

    “This is not a replacement for education or technology, but we think for some people it is a very necessary thing to have with it.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EASD Annual Meeting; Sept 27–Oct 1, 2021

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.